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Abstract
Background: Compared with the general population, individuals with severe mental illness (SMI) have increased
prevalence rates of obesity and greater risk for cardiovascular disease. This study aimed to investigate the effects of
a long term nutritional intervention on body weight, body fat and cardiovascular risk factors in a large number of
patients with SMI.
Methods: Nine hundred and eighty-nine patients with a mean ± S.D age of 40 ± 11.7 yrs participated in a 9 mo
nutritional intervention which provided personalised dietetic treatment and lifestyle counselling every two weeks.
Patients had an average body mass index (BMI) of 34.3 ± 7.1 kg.m
-2 and body weight (BW) of 94.9 ± 21.7 kg. Fasted
blood samples were collected for the measurement of glucose, total cholesterol, triglycerides and HDL- cholesterol.
All measurements were undertaken at baseline and at 3 mo, 6 mo and 9 mo of the nutritional intervention.
Results: Four hundred and twenty-three patients of 989 total patients’ cases (42.8%) dropped out within the first
3 months. Two hundred eighty-five completed 6 months of the program and 145 completed the entire 9 month
nutritional intervention. There were progressive statistically significant reductions in mean weight, fat mass, waist and
BMI throughout the duration of monitoring (p < 0.001). The mean final weight loss was 9.7 kg and BMI decreased to
30.7 kg.m
-2 (p < 0.001). The mean final fat mass loss was 8.0 kg and the mean final waist circumference reduction
was 10.3 cm (p < 0.001) compared to baseline. Significant and continual reductions were observed in fasting plasma
glucose, total cholesterol and triglycerides concentrations throughout the study (p < 0.001).
Conclusion: The nutritional intervention produced significant reductions in body weight, body fat and improved
the cardiometabolic profile in patients with SMI. These findings indicate the importance of weight-reducing
nutritional intervention in decreasing the cardiovascular risk in patients with SMI.
Background
Psychiatric patients have a high prevalence of obesity or
a greater risk for weight gain due to antipsychotic (neu-
roleptic) treatment. Recent studies suggest that patients
with severe mental illness (SMI) might have an even
higher proportion of obesity than individuals in the gen-
eral population. For example, Dickerson et al. compared
149 psychiatric patients with matched controls and
found that prevalence of obesity was twice as high as
the general US adult population (men 41 vs. 20% and
women 50 vs. 27%) [1]. As early as the mid-1960s, asso-
ciations between conventional neuroleptic treatment
and metabolic abnormalities were reported. Atypical
antipsychotics are newer drugs that are increasingly
replacing the conventional neuroleptics due to better
efficacy and side effects profile. However evidence sug-
gests that some of the atypical antipsychotics may have
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betes and dyslipidemia [2].
It is well demonstrated that excessive body weight is a
clearly established factor for type 2 diabetes and cardio-
vascular disease in the general population. Changes in
some glucose and lipid parameters are commonly
reported in patients with all forms of severe mental ill-
ness (SMI) (psychosis, depression, bipolar disease).
These metabolic changes are probably related to a com-
bination of genetic predisposition, lifestyle factors and
psychotropic treatments [3]. Moreover, the burden of
weight gain may affect compliance with medication
which may predispose psychiatric patients in great
health risk. Thus, psychiatric patients appear to be at
increased risk of high morbidity and mortality [4].
It becomes clearly understood that controlling and
decreasing the weight gain of psychiatric patients should
be a priority within their treatment program. It is
argued that managing obesity in SMI patients is a chal-
lenging task as these patients may have impaired atten-
tion, motivation and memory that may impair their
ability to follow weight loss program. Behavioral
approaches that combine reduced dietary intake and
increased physical activity are recommend as most
favorable and effective strategy for weight management
than pharmacological approaches in psychiatric obese
population [5]. In healthy overweight and obese indivi-
duals life style interventions through diet and exercise
produce significant weight loss and reductions in body
fat. Recent studies of dietary and behavioral modifica-
tion interventions have found small significant weight
decreases in SMI patients on antipsychotic medication
over short-term intervals [6]. Evidence also suggests sig-
nificant improvements in the metabolic profile of obese
psychiatric patients after weight loss interventions [7].
The long-term effects of nutritional interventions on
several adiposity parameters and cardiometabolic para-
meters are not clearly understood. Previous studies have
mainly reported the effects of weight loss on body
weight and little is known for the effects on body com-
position. In addition, although metabolic abnormalities
are well documented in patients taking antipsychotics
[8], the effects of weight loss on metabolic regulation is
not clearly described in psychiatric patients. The pre-
vious evidence is derived from controlled clinical trials
of small number of patients or from a few naturalistic
observational studies of inpatients. Thus, more observa-
tional studies of large number of psychiatric outpatients
are required to assess management of weight gain and
of metabolic disorders. In addition, previous conclusions
are tempered by the short term duration of the studies
and the small sample sizes used in those studies. There-
fore the present study aimed to investigate the effects of
a long term nutritional intervention on body weight,
body composition and cardiovascular risk factors in a
large number of patients with severe mental illness.
Methods
Subjects with SMI
A total of 989 psychiatric patients were recruited for the
study (774 women and 215 men) and gave written
informed consent. Patients were recommended to parti-
cipate in the study by psychiatrists working either pri-
vately or in hospital offices in Thessaloniki (Greece). The
study was carried out from January 2007 to November
2009. The study has been approved by the ethical com-
mittee of the Technological Educational Institute of
Thessaloniki (Ref. No 20111). All patients were found
competent by an independent psychiatrist, who was not
involved in the study, to participate and to follow weight
loss intervention at the enrollment visit. All patients con-
tinued on treatment with their medication. Antipsychotic
drugs were being used by 28% of patients (n = 274), 30%
of patients were taking antidepressants (n = 297), 23% of
patients were taking both antipsychotics & antidepres-
sants (n = 230) and 19% of patients (n = 288) were taking
antipsychotics & antidepressants, as well other types of
medication (e.g. acholytic, antiparkinson, antiepileptic).
Medication was kept constant for every patient.
Anthropometric measurements
Prior to the baseline assessment, patients visited the die-
titian for familiarization with study design and measure-
ments. The dietitian explained the study design and
measurements thoroughly and then patients’ relevant
questions were answered.
At the beginning of the study (baseline-visit A), at 3 mo,
6m oa n d9m oo ft h en u t r i t i o n a li n t e r v e n t i o n( v i s i tB ,C
and visit D respectively), several anthropometric measure-
ments were undertaken to assess the outcome of the nutri-
tional intervention program. All the measurements were
carried out by the same two dietitians.
Body weight was measured on a standing scale cali-
brated to 0.1 kg (Seca digital scale). Body height was
measured on a wall-mounted stadiometer. The subjects
stood with legs parallel and shoulder-width apart. Waist
circumference (WC) was measured at the end of normal
expiration at the minimal waist (smallest horizontal cir-
cumference above the umbilicus and below the xiphoid
process). Hip circumference (HP) was measured around
the maximum circumference over the buttocks.
Body Fat was measured by the bioelectrical impedance
analysis (BIA, Akern version 1.31). During the 9 mo per-
iod, subjects were asked to visit the nutrition unit every
2 wks. At these visits, body weight, waist circumference
and body fat were measured by the same dietitian. For
patients who dropped out, body weight was recorded
and BMI was calculated when the drop out occurred.
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The intervention period lasted 9 months and consisted
of 2 phases: a familiarization visit and an intensive 9
month nutritional intervention period. The dietary
advice for weight control was given in each patient by a
registered dietitian. It was based on a Mediterranean-
style diet in combination with personalized healthy
nutrition counselling. Each patient received personalized
dietary regimen on the basis of dietary history and life-
style. The dietary regimen was characterized by a mod-
erate consumption of carbohydrates (50-55% of total
energy per day) and a high fiber content, 15-20% protein
and a fat intake of 30-35% of total energy per day.
Moreover, patients were advised to consume fruits,
vegetables, whole grains (legumes, rice, maize, and
wheat) daily and to increase their consumption of olive
oil. The dietary regimen was designed to produce an
energy deficit of 500 kcal per week. The patients were
visiting the dietitian every two weeks to discuss weight
changes and treatment goals.
The Resting Metabolic Rate (RMR) was measured by
indirect calorimetry (Fitmate Pro, Cosmed USA Inc.)
during their first visit. All patients completed a physical
activity record. RMR was multiplied by an activity factor
of 1.3-1.5, according to the physical activity level of each
patient, and daily energy requirements of each patient
were estimated. The intervention program consisted pri-
marily of dietary counseling, physical activity counseling
and behavioral interventions in order to aid patients’
adherence to a healthy life plan during the nutritional
intervention. Counseling sessions were undertaken indi-
vidually by each patient and included teaching healthful
weight management techniques, meal planning, food
shopping and preparation, portion control, techniques
to differentiate emotional from psychological hunger
etc. In terms of physical activity counseling, subjects
were instructed to participate in light or moderate exer-
cise at least 30 min 3-5 times per week.
Biochemical measurements
Biochemical measurements were undertaken at the
beginning of the study (baseline-Visit A), at 3 mo (Visit
B), 6 mo (Visit C) and 9 mo (Visit D) of the nutritional
intervention. Data regarding plasma glucose, total cho-
lesterol, HDL cholesterol and triglycerides were
recorded by the dietitian.
Statistical Analysis
Data are expressed as means and standard deviations
(SD). Within-subject paired t-tests compared initial vs
end point measures for subjects that completed the 9
mo intervention. Comparisons between completers and
drop-outs were performed using independent sample t-
tests. In order to compensate for missing data due to
withdrawal, the last-observation-carried-forward (LOCF)
method was used and paired t-tests were performed
against the LOCF data as well. Correlation analysis was
also carried out for associations between body weight
change and body fat percentage (BF %) change over
time (baseline to 3 mo, 6 mo and 9 mo). Statistical sig-
nificance was taken as P < 0.05. The statistical analysis
was processed with SPSS 11 for Windows (SPSS, Inc.,
Chicago, IL, USA).
Results
Characteristics of SMI subjects and their baseline
condition
Figure 1 presents the participants’ flow during the 9 mo
nutritional intervention. From the first drop-out sample,
82 subjects were males and 341 subjects were females,
with average age 40.7 ± 11.8 y and average body weight
94.9 ± 21.2 kg. From the second drop-out sample, 70
subjects were males and 211 subjects were females, with
average age 40.1 ± 11.2 y and average body weight 95.6 ±
23.1 kg (Figure 1). From the 3
rd drop-out sample, 28 sub-
jects were males and 112 females. Reasons for dropping
out of the study included an inability or unwillingness to
Baseline 
n=989 
1
st Drop-out sample (n=423) 
Age (yrs) 40.7 ± 11.8 
Males, n=82 (19.4%); Females, n=341 (80.6%)
n=566 
Completers at Visit B  
2nd Drop-out sample (n=281) 
Age (yrs) 40.1 ± 11.2 
Males, n=70 (24.9%); Females, n=211 (75%)
n=285 
Completers at Visit C 
3rd Drop-out sample (n=140) 
Age (yrs) 39.9 ± 11.1 
Males, n=28 (20%); Females, n=112 (80%)
n=145 
Completers at Visit D 
Figure 1 Participants’ Flow.
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blems, health problems and transportation. Table 1
shows the characteristics of the subjects obtained from
the baseline investigation. At baseline, all patients were
classified obese (BMI > 30 kg
.m
-2) with an average body
weight of 94.9 ± 21.7 kg and an average BMI of 34.3 ±
6.9 kg
.m
-2. The ratio of men that completed the 9 mo
nutritional intervention (completers) was significantly
greater than the ratio of women (P = 0.009). No signifi-
cant differences were found in anthropometric and bio-
chemical characteristics between drop-outs and
completers at baseline (P > 0.05) (Table 1).
Effect of the nutritional intervention on body
composition
Table 2 shows the change in adiposity parameters from
baseline to 9 mo of the nutritional intervention in
completers and drop-outs. Body weight, BMI, waist
and hip decreased significantly from baseline to 3 mo,
6 mo and 9 mo of the intervention in both completers
and drop-outs (P < 0.001). In addition, body fat %,
body fat mass (kg) decreased significantly at 3 mo, 6
mo and 9 mo of the nutritional intervention relative to
baseline in completers (P < 0.001). Baseline measure-
ments of weight and BMI were not significantly differ-
ent between completers and drop-outs (Table 2).
Completers at visit B (3 mo) and visit C (6 mo) had
significantly lower weight and BMI than patients who
dropped out before visit B and visit C, respectively.
Weight and BMI were not significantly different
between completers at visit D (9 mo) and patients who
dropped out before visit D. The average change of
weight and BMI, however, was significantly higher in
completers than drop-outs at 9 mo (Δ (weight) 9.7 ±
8.4 vs 5.9 ± 6.2 respectively, P < 0.001; (Δ (BMI) 3.6 ±
3.0 vs 2.1 ± 2.2 respectively, P < 0.001 ). RMR
decreased significantly in completers at visit B and C
compared to baseline (P < 0.001) (Table 2). The effect
of nutritional intervention on body weight and body
composition was confirmed when LOCF analysis was
performed (Table 3). There were positive associations
between change in body weight and BF % change in
SMI patients (Visit A to Visit B, r = 0.46 (P < 0.001);
Visit A to Visit C, r = 0.46 (P < 0.001); Visit A to Visit
C, r = 0.62 (P < 0.001). There was no significant differ-
ence in weight loss between patients receiving different
psychotropic medication (P > 0.05).
Effects of the nutritional intervention on biochemical
parameters
Table 4 shows the change in plasma glucose and plasma
lipid concentrations. Fasting plasma glucose concentra-
tions and total cholesterol concentrations decreased sig-
nificantly from baseline to 3 mo, 6 mo and 9 mo of the
intervention (P < 0.05, P < 0.001, P < 0.001, respec-
tively). Fasting plasma triglycerides concentrations
decreased significantly at 6 mo and 9 mo of the nutri-
tional intervention compared to baseline (P < 0.001).
The nutritional intervention produced a small decrease
in HDL-cholesterol compared to baseline but this was
not statistically significant (P > 0.05) (Table 4). The
effect of nutritional intervention on plasma glucose and
plasma lipids was confirmed when LOCF analysis was
performed (Table 3).
Table 1 Baseline characteristics
Total subjects Completers Drop-outs p-values
Males (n (%) 215 (21.8%) 44 (30.3%)* 171 (20.3%) 0.009
Females (n (%) 774 (78.4%) 101 (69.7%) 673 (79.7%)
nn
Age (years) 989 40.2 ± 11.8 (19-80) 145 38.9 ± 12.1 844 40.4 ± 11.5 0.14
Weight (kg) 989 94.9 ± 21.7 145 95.5 ± 21.6 844 94.8 ± 21.7 0.70
Height (m) 1.66 ± 0.09
BMI (kg
.m
-2) 34.3 ± 6.9 145 34.4 ± 7.1 844 34.4 ± 6.9 0.97
Waist (cm) 974 108.9 ± 17.5 144 109.8 ± 18.3 832 108.8 ± 17.4 0.52
Hip (cm) 974 118.4 ± 34.1 144 117.3 ± 11.9 832 117.4 ± 11.5 0.92
Waist/Hip ratio 0.92 ± 0.12 0.94 ± 0.12 0.93 ± 0.11 0.13
Fat mass (%) 803 38.3 ± 8.03 121 37.4 ± 8.13 682 38.4 ± 8.02 0.20
Fat mass (kg) 36.8 ± 13.7 36.1 ± 14.4 36.9 ± 13.5 0.54
RMR 776 1608 ± 439.9 125 1644 ± 408 651 1601 ± 446 0.32
Total Cholesterol (mg/dl) 867 209.4 ± 41.4 139 212.1 ± 43.9 728 208.8 ± 40.9 0.40
HDL-Cholesterol (mg/dl) 755 49.9 ± 14.9 120 50.2 ± 18.6 635 49.9 ± 14.2 0.89
Triglycerides (mg/dl) S 857 151.6 ± 107.8 139 161 ± 114 718 150 ± 107 0.28
Glucose (mg/dl) 884 97.8 ± 21.8 141 98.7 ± 26.5 743 97.6 ± 20.8 0.58
Values are mean ± SD
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This study shows that a personalized nutritional inter-
vention is effective in decreasing adiposity and metabolic
parameters in patients with severe mental illness. Pre-
vious lifestyle interventions have clearly reported weight
loss in patients with severe mental illness but these
results were derived from small number of patients and
over short term intervals [6,9]. The present study used a
large sample size and a 9 month nutritional intervention
in order to investigate changes on both adiposity and
metabolic parameters in patients with severe mental
illness.
The present study found a progressive statistically sig-
nificant decrease in mean adiposity parameters through-
out the duration of monitoring compared to baseline.
There is a paucity of clinical trials of management of
obesity in patients with severe mental illness. The ran-
domized controlled studies found significant weight
reductions or modest reductions on body weight in
patients taking antipsychotic medication [10-17]. A
small number of nonrandomized controlled studies
reported significant weight change [18,19], while Ball
and colleagues [20] reported no significant weight
change between the nonrandomized intervention group
and control group. The present study found a mean
weight loss at 3 months of 4.3 kg which is in agreement
with other studies [11-18]. However, the evidence is
poor for the long term effects of nutritional intervention
on adiposity parameters. In our study, the mean weight
loss of 7.4 kg at 6 months is greater compared to
previous open studies [16,21,22]. The mean weight
reduction of 9.6 kg at 9 mo was progressive and signifi-
cant and exceeds the weight loss achieved in previous
long term studies with behavioral treatment programs
[23,24]. In addition weight loss was also found signifi-
cant and continual in the drop-outs which probably
indicates a general efficacy of the present nutritional
intervention. The body weight management in our
patients was undertaken with personalized dietetic treat-
ment and lifestyle counseling. Patients were seen by a
dietitian who assessed weight changes and treatment
goals every two weeks. The greater weight loss in our
study might indicate that a personalized nutritional
intervention can produce significant weight loss in psy-
chiatric patients who manage to adhere to the nutri-
tional intervention for more than three months.
The present nutritional intervention not only reduced
body weight but demonstrated continual significant
decrease in body fat mass (kg) and percent of body fat
(%) in our patients. Skouroliakou et al. [17] reported sig-
nificant reduction in fat mass but in the short term. The
present decrease in fat mass is demonstrated for the first
time in a long term nutritional intervention in SMI
patients. The mean fat mass reduction was continual and
significant throughout the study (e.g. 6 kg fat mass loss at
3m o ;5 . 9k gf a tm a s sl o s sa t6m oa n d8k gf a tm a s sl o s s
at 9 mo). BMI was also significantly decreased verifying
the decrease in total body fat and general obesity. More-
over waist circumference, a well documented proxy for
visceral obesity [25], was significantly decreased in our
Table 2 Changes in parameters of adiposity during the 9 mo nutritional intervention
Visit A (Baseline) vs
Visit B (3 mo)
Visit A (Baseline) vs
Visit C (6 mo)
Visit A (Baseline) vs
Visit D (9 mo)
Completers Drop-outs
(before visit B)
Completers Drop-outs
(before visit C)
Completers Drop-outs
(before visit D)
Weight(Kg) 94.9 ± 22.1 (n = 566) 94.9 ± 21.2
(n = 423)
94.3 ± 20.9 (n = 285) 95.6 ± 23.1
(n = 281)
95.1 ± 21.9 (n = 145) 93.4 ± 19.8
(n = 140)
90.6 ± 21.2
*, a 94.5 ± 21.4* 86.8 ± 19.3
†,b 92.4 ± 22.4
† 85.5 ± 19.4
†† 87.4 ± 18.8
††
BMI (kg
.m
-2) 34.3 ± 7.1 (n = 554) 34.5 ± 6.8 34.1 ± 6.9 (n = 282) 34.4 ± 7.3 34.3 ± 7.2 (n = 144) 33.9 ± 6.5
32.8 ± 6.8
*, a 34.4 ± 6.9* 31.5 ± 6.4
†,b 33.3 ± 7.2
† 30.6 ± 6.2
†† 31.8 ± 6.3
††
Waist (cm) 108.3 ± 17.6 (n = 540) 108.5 ± 17.6 (n = 270) 109.4 ± 18.7 (n = 144)
103.7 ± 17.1* 100.8 ± 16.3
† 99.1 ± 17.9
††
Hip (cm) 119.2 ± 44.6 (n = 540) 116.8 ± 11.3 (n = 270) 116.9 ± 12.3 (n = 140)
113.5 ± 11.3* 110.2 ± 10.2
† 108.4 ± 10.6
††
Body Fat (%) 38.4 ± 8.1 (n = 275) 37.7 ± 8.4 (n = 121) 36.9 ± 8.6 (n = 50)
36.2 ± 8.3* 31.7 ± 11.7
† 30.5 ± 10.3
††
Body Fat(kg) 36.4 ± 14.1 (n = 275) 35.9 ± 13.9 n = 121) 35.8 ± 14.2 (n = 50)
32.7 ± 13.3* 30.1 ± 12.0
† 27.7 ± 11.3
††
RMR 1563.0 ± 391.6 (n = 107) 1567.2 ± 383.5 (n = 63) 1642.1 ± 520.0 (n = 21)
1469.9 ± 443.3* 1432.9 ± 452.5
† 1430.5 ± 457.0
Values are means ± SD. n refers to number of adiposity measurements obtained in each visit B, C and D, consequently the same number of baseline
measurements is used for the comparisons. Significance differences were determined by paired t-tests; *P < 0.001 for the difference between baseline and visit B;
†P < 0.001 for the difference between baseline and visit C,
††P < 0.001 for the difference between baseline and visit D. Symbols
a, b show significant differences
by independent t-tests between completes and drop-outs at visit B and C respectively (
a P < 0.01,
bP = 0.002).
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loss produced a decrease in RMR. These findings in SMI
patients are comparable to reduction of obesity-related
factors with lifestyle modification within the general
obese population [27]. Recent consensus guidelines for
patients with severe mental illness recommend the mea-
surements of both BMI and WC to monitor cardiovascu-
lar risk factors in this population [28]. The reductions
found in waist circumference and body mass in our SMI
patients indicate improvements in the risk factors asso-
ciated with cardiovascular disease.
The reduction in fasting glucose was significant
throughout the nutritional intervention compared to
baseline. This is important since abnormalities in glu-
cose metabolism have been associated with the use of
antipsychotic treatment [29]. The significant reduction
in fasting glucose may be primarily due to weight loss
since medication was kept constant. Similarly there were
significant reductions in total cholesterol and triglycer-
ides during the 9 month nutritional intervention. These
reductions in lipids concentrations are also important
since psychiatric patients have been shown to have
elevated dyslipidemia compared to general population
[30]. Both total cholesterol and triglycerides dropped
significantly since weight loss became significant
throughout the intervention. The present results justify
the important use of weight reducing programs and
especially of nutritional intervention in the management
of metabolic dysregulation in patients with severe men-
tal illness.
Limitations
By design the present study did not include a control
group, so it is unknown whether a similar group of
obese patients would have lost or gained weight over
the same time period. Ideally, longer term randomized
controlled trials are needed to assess the effectiveness of
the nutritional interventions. In addition, we can not
draw conclusions on the long-term effectiveness of the
intervention by means of weight maintenance as a fol-
low-up period was not included. However, the present
results are derived from a relatively large sample com-
pared to previous shorter term or longer term studies of
small-subject numbers. Another limitation of the
Table 3 Last Observation Carried Forward Analysis (LOCF)
n Visit A (Baseline) Visit B (3 mo) Visit C (6 mo) Visit D (9 mo)
Weight(Kg) 989 94.9 ± 21.7 92.4 ± 21.3* 91.8 ± 21.3
† 91.7 ± 21.3
††
BMI (kg
.m
-2) 989 34.3 ± 6.9 33.5 ± 6.9* 33.3 ± 6.9
† 33.2 ± 6.9
††
Waist (cm) 974 108.9 ± 17.5 106.4 ± 17.3* 105.8 ± 17.6
† 105.5 ± 17.8
††
Hip (cm) 118.4 ± 34.1 115.23 ± 11.4* 114.6 ± 11.5
† 114.5 ± 11.6
††
Body Fat (%) 803 38.2 ± 8.0 37.5 ± 8.2* 37.2 ± 8.3 37.1 ± 8.3
††
Body Fat (kg) 36.8 ± 13.7 35.5 ± 13.6* 35.1 ± 13.6 34.9 ± 13.6
††
RMR (kcal) 776 1608.0 ± 439.9 1600.6 ± 437.6 1596.9 ± 439.4
† 1595.9 ± 436.3
††
Total Cholesterol (mg/dl) 867 209.4 ± 41.4 208.1 ± 40.9* 207.5 ± 40.9
† 207.2 ± 40.9
††
HDL-Cholesterol (mg/dl) 755 49.9 ± 14.9 49.8 ± 13.9 49.8 ± 13.8 49.7 ± 13.8
Triglycerides (mg/dl) 857 151.6 ± 107.8 150.2 ± 104.1 149.4 ± 103.3
† 148.0 ± 101.7
††
Glucose (mg/dl) 884 97.8 ± 21.8 97.3 ± 20.5* 97.3 ± 20.6
† 97.2 ± 20.4
††
Significance differences were determined by paired t-tests; *P < 0.001 for the difference between baseline and visit B;
†P < 0.001 for the difference between
baseline and visit C,
††P < 0.001 for the difference between baseline and visit D.
Table 4 Change in biochemical parameters during the 9 mo nutritional intervention
Visit A (Baseline) vs Visit B
(3 mo)
Visit A (Baseline) vs Visit C
(6 mo)
Visit A (Baseline) vs Visit D
(9 mo)
nn n
Total Cholesterol (mg/dl) 136 214.8 ± 42.1 66 214.3 ± 44.2 25 215.3 ± 51.1
206.8 ± 39.9* 200.6 ± 43.3
† 190.4 ± 44.2
††
HDL-Cholesterol (mg/dl) 54 47.9 ± 24.6 38 48.7 ± 28.3 17 50.3 ± 12.5
45.1 ± 12.5 43.9 ± 10.3 47.5 ± 10.2
††
Triglycerides (mg/dl) 135 162.4 ± 113.7 65 175.8 ± 112.9 25 213.1 ± 167.1
153. 3 ± 89.9* 158.4 ± 91.8
† 135.3 ± 74.4
††
Glucose (mg/dl) 139 98.3 ± 26.6 68 99.1 ± 20.2 25 100.8 ± 17.6
95.3 ± 18.5* 95.3 ± 15.9
† 96.5 ± 16.2
††
Values are means ± SD. n refers to number of biochemical measures obtained in each visit B, C and D. Significance differences were determined by paired
t-tests; *P < 0.001 for the difference between baseline and visit B;
†P < 0.001 for the difference between baseline and visit C,
††P < 0.001 for the difference
between baseline and visit D.
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psychiatric disorders can be a significant barrier to
weight loss success in obese individuals, thus discon-
tinuance of the study could have been expected. In a
meta-analysis of compliance studies, DiMatteo et al.
showed that patients with depression had a 3-fold
higher rate of noncompliance with medical treatments,
including diet recommendations [31]. However, the sig-
nificant results from LOCF analysis confirm the efficacy
of the 9 mo nutritional intervention in terms of success-
ful weight loss and improvement of the metabolic pro-
file in our SMI patients.
Conclusions
This study has important clinical implication, indicating
the effectiveness of a simple nutritional intervention on
adiposity and lipid regulation which is important in psy-
chiatric patients who are a high risk group for the devel-
opment of cardiovascular disease. The present results
show that obese patients with severe mental illness can
achieve weight control and improve cardiometabolic
p r o f i l eb yf o l l o w i n gas i m p l ep e r s o n a l i z e dn u t r i t i o n a l
program for 9 months.
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